American Heart Journal
Volume 151, Issue 3 , Pages 755.e1-755.e6 , March 2006

The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events

  • Carol E. Koro, PhD

      Affiliations

    • GlaxoSmithKline, Inc., Collegeville, PA
    • ,
  • Steven J. Bowlin, DO, PhD

      Affiliations

    • GlaxoSmithKline, Inc., Collegeville, PA
    • ,
  • Timothy E. Stump, MA

      Affiliations

    • Regenstrief Institute, Inc., Indianapolis, IN
    • ,
  • Dennis L. Sprecher, MD

      Affiliations

    • GlaxoSmithKline, Inc., Collegeville, PA
    • ,
  • William M. Tierney, MD

      Affiliations

    • Regenstrief Institute, Inc., Indianapolis, IN
    • Indiana University School of Medicine, Indianapolis, IN
    • Corresponding Author InformationReprint requests: William M. Tierney, MD, Room M200-OPW, Wishard Memorial Hospital, 1001 West Tenth Street, Indianapolis, IN 46202.

Received 5 September 2005 ,Accepted 6 December 2005.

References 

  1. Mokdad AH, Marks JS, Stroup DF, et al. Actual causes of death in the United States, 2000. JAMA. 2004;291:1238–1245
  2. D'Agostino RB, Grundy S, Sullivan LS, et al. for the CHD Risk Prediction Group Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180–197
  3. Lipid Research Clinics Program . The Lipid Research Clinics Coronary Primary Prevention Trial Results: I, reduction in the incidence of coronary heart disease. JAMA. 1984;251:351–374
  4. Lipid Research Clinics Program . The Lipid Research Clinics Coronary Primary Prevention Trial Results: II, the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365–374
  5. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med. 1990;323:1112–1119
  6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2508–2509
  7. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102:21–27
  8. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol . Final mortality follow-up. Report of the Committee of Principal Investigators. Lancet. 1984;2:600–604
  9. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237–1245
  10. Gordon DL, Rifkind BM. High-density lipoprotein—the clinical implications of recent studies. N Engl J Med. 1989;321:1311–1316
  11. Gotto AM. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J. 2002;144(Suppl):33–42
  12. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol. 2000;86(Suppl):19L–22L
  13. Gotto AM, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary vents in the Air Force/Texas Coronary Atherosclerosis Prevention Study. Circulation. 2000;101:477–484
  14. Tierney WM, Miller ME, Hui SL, et al. Practice randomization and clinical research: the Indiana experience. Med Care. 1991;29:JS57–JS64
  15. Agency for Healthcare Research and Quality . Fact sheet: primary care practice–based research networks. Accessed January 26, 2005 at http://www.ahrq.gov/research/pbrnfact.htm
  16. McDonald CJ, Overhage JM, Tierney WM, et al. The Regenstrief Medical Record System: a quarter century experience. Int J Med Inf. 1999;54:225–253
  17. Overhage JM, McDonald CJ, Tierney WM. Design and implementation of the Indianapolis Network for Patient Care and Research. MLA Bull. 1995;83:48–56
  18. Tierney WM, McDonald CJ. Practice databases and their uses in clinical research. Stat Med. 1991;10:541–557
  19. Chapman MJ, Assmann G, Fruchart JC, et al. European Consensus Panel on HDL-C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid—a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin. 2004;20:1253–1268
  20. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. JAMA. 2001;285:1585–1591
  21. McDonald CJ, Hui SL, Smith DM, et al. Reminders to physicians from an introspective computer medical record. A two-year randomized trial.. Ann Intern Med. 1984;100:130–138

 The authors are solely responsible for the content of this article that represents their opinions and not necessarily their respective institutions.

 This study was funded by a research grant from GlaxoSmithKline to Dr Tierney.

PII: S0002-8703(05)01067-7

doi: 10.1016/j.ahj.2005.12.007

American Heart Journal
Volume 151, Issue 3 , Pages 755.e1-755.e6 , March 2006

Article Tools